EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Red Blood Cell Membrane Vesicles for siRNA Delivery: A Biocompatible Carrier With Passive Tumor Targeting and Prolonged Plasma Residency

Giulia Della Pelle iD, Bostjan Markelc iD, Tim Bozic, Jernej Šribar, Igor Krizaj, Kristina Zagar Soderznik, Samo Hudoklin, Mateja Erdani Kreft iD, Iztok Urbančič, Matic Kisovec iD, Marjetka Podobnik, Nina Kostevšek

International Journal of Nanomedicine · 2025-03 · Volume 20 · 3269-3301

DOI: 10.2147/ijn.s504644 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Nanomedicine, 2025-03. Verfasst von Giulia Della Pelle und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department for Nanostructured Materials, Jožef Stefan Institute, Ljubljana, 1000, Slovenia. Hauptthemen laut MEDLINE: RNA, Small Interfering, Erythrocyte Membrane, Melanoma, Experimental, Drug Carriers. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 128 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite many advances in gene therapy, the delivery of small interfering RNAs is still challenging. Erythrocytes are the most abundant cells in the human body, and their membrane possesses unique features. From them, erythrocytes membrane vesicles can be generated, employable as nano drug delivery system with prolonged blood residence and high biocompatibility.

Methods

Human erythrocyte ghosts were extruded in the presence of siRNA, and the objects were termed EMVs (erythrocyte membrane vesicles). An ultracentrifugation-based method was applied to select only the densest EMVs, ie, those containing siRNA. We evaluated their activity in vitro in B16F10 cells expressing fluorescent tdTomato and in vivo in B16F10 tumor-bearing mice after a single injection.

Results

The EMVs had a negative zeta potential, a particle size of 170 nm and excellent colloidal stability after one month of storage. With 0.3 nM siRNA, more than 75% gene knockdown was achieved in vitro, and 80% was achieved in vivo, at 2 days PI at 2.5 mg/kg. EMVs mostly accumulate around blood vessels in the lungs, brain and tumor. tdTomato fluorescence steadily decreased in tumor areas with higher EMVs concentration, which indicates efficient gene knockdown. Approximately 2% of the initial dose of EMVs was still present in the plasma after 2 days.

Conclusion

The entire production process of the purified siRNA-EMVs took approximately 4 hours. The erythrocyte marker CD47 offered protection against macrophage recognition in the spleen and in the blood. The excellent biocompatibility and pharmacokinetic properties of these materials make them promising platforms for future improvements, ie, active targeting and codelivery with conventional chemotherapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA, Small InterferingErythrocyte MembraneMelanoma, ExperimentalDrug CarriersAnimalsHumansMiceCell Line, TumorParticle SizeMice, Inbred C57BLBiocompatible Materials

Stichwörter der Autor:innen

EPR effectRNA interferencebiomimeticmelanomananomedicine

Substanzen

RNA, Small InterferingDrug CarriersBiocompatible Materials

Autor:innen und Institutionen

  • Department for Nanostructured Materials, Jožef Stefan Institute, Ljubljana, 1000, Slovenia.
  • Jožef Stefan International Postgraduate School, Ljubljana, 1000, Slovenia.
  • Department of Experimental Oncology, Institute of Oncology Ljubljana, Ljubljana, 1000, Slovenia.
  • Department of Molecular and Biomedical Sciences, Jožef Stefan Institute, Ljubljana, 1000, Slovenia.
  • Institute of Cell Biology, Faculty of Medicine, University of Ljubljana, Ljubljana, 1000, Slovenia.
  • Laboratory of Biophysics, Condensed Matter Physics Department, Jožef Stefan Institute, Ljubljana, 1000, Slovenia.

ORCID-Profile: Giulia Della Pelle, Bostjan Markelc, Mateja Erdani Kreft, Matic Kisovec

Zitieren

APA

Della Pelle, G., Markelc, B., Bozic, T., Šribar, J., Krizaj, I., Zagar Soderznik, K., Hudoklin, S., Kreft, M. E., Urbančič, I., Kisovec, M., Podobnik, M., & Kostevšek, N. (2025). Red Blood Cell Membrane Vesicles for siRNA Delivery: A Biocompatible Carrier With Passive Tumor Targeting and Prolonged Plasma Residency. International Journal of Nanomedicine, Volume 20, 3269-3301. https://doi.org/10.2147/ijn.s504644

Vancouver

Della Pelle G, Markelc B, Bozic T, Šribar J, Krizaj I, Zagar Soderznik K, et al. Red Blood Cell Membrane Vesicles for siRNA Delivery: A Biocompatible Carrier With Passive Tumor Targeting and Prolonged Plasma Residency. International Journal of Nanomedicine. 2025;Volume 20:3269-3301. doi:10.2147/ijn.s504644

BibTeX
@article{DellaPelle2025,
  author = {Della Pelle, Giulia and Markelc, Bostjan and Bozic, Tim and Šribar, Jernej and Krizaj, Igor and Zagar Soderznik, Kristina and Hudoklin, Samo and Kreft, Mateja Erdani and Urbančič, Iztok and Kisovec, Matic and Podobnik, Marjetka and Kostevšek, Nina},
  title = {Red Blood Cell Membrane Vesicles for siRNA Delivery: A Biocompatible Carrier With Passive Tumor Targeting and Prolonged Plasma Residency},
  journal = {International Journal of Nanomedicine},
  year = {2025},
  volume = {Volume 20},
  pages = {3269--3301},
  doi = {10.2147/ijn.s504644}
}
Kostenlos starten →